This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Bayer Aktiengesellschaft. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Julia Glunz: Innovator in Antibody Research
Introduction
Julia Glunz is a prominent inventor based in Essen, Germany. She has made significant contributions to the field of antibody research, particularly with her innovative work on anti-A2AP antibodies. Her research focuses on the development of isolated antibodies that have the potential to enhance medical treatments.
Latest Patents
Julia Glunz holds a patent for "Anti-A2AP antibodies and uses thereof." This invention relates to an isolated antibody or antigen-binding fragment that binds to human A2AP. The isolated antibody is notable for its ability to cross-react with rabbit and/or cynomolgus A2AP, while not inhibiting human plasmin activity. Furthermore, it increases plasmin-mediated clot lysis in the presence of A2AP. This patent represents a significant advancement in therapeutic applications.
Career Highlights
Julia Glunz is associated with Bayer Aktiengesellschaft, a leading global pharmaceutical and life sciences company. Her work at Bayer has allowed her to contribute to groundbreaking research and development in the field of antibodies. With her expertise, she has been able to push the boundaries of what is possible in medical science.
Collaborations
Julia collaborates with esteemed colleagues, including Stefan Heitmeier and Cindy Schulenburg. These partnerships enhance her research efforts and contribute to the innovative environment at Bayer.
Conclusion
Julia Glunz is a remarkable inventor whose work on anti-A2AP antibodies has the potential to transform medical treatments. Her contributions to the field of antibody research are invaluable, and her collaborations further strengthen her impact in the industry.